SZSE Ticker: 300878

Zhejiang Wecome Pharmaceutical Company Limited

浙江维康药业股份有限公司

维康

WECOME

Listing Date: 2020-08-24

Board: GEM

Industry Classification: Manufacturing

Weikang Pharmaceutical: At present, there is no cooperation project between the company and Suzhou Wangshan Wangshui Biological Co., Ltd.

Weikang Pharmaceutical: At present, there is no cooperation project between the company and Suzhou Wangshan Wangshui Biological Co., Ltd.

Weikang Pharmaceutical: At present, there is no cooperation project between the company and Suzhou Wangshan Wangshui Biological Co., Ltd._ Oriental Fortune Net

Weikang Pharmaceutical: The company and Yingkerui entered the stage of in-depth cooperation. The cooperation projects and categories have also been further extended and expanded_ Oriental Fortune Net

Weikang Pharmaceutical (300878): Holding 2021 Online Performance Briefing-CFi.CN Zhongcai.com

Weikang Pharmaceutical: Huangjia Ruangan Granules, the company's product under development, is a 1.1 class of innovative traditional Chinese medicines

Weikang Pharmaceutical: The company's product under development, Huangjia Ruangan Granules, is a category 1.1 innovative traditional Chinese medicine drug_Oriental Fortune Network

Weikang Pharmaceutical: The two parties will increase cooperation in the research of new preparations, and further strengthen cooperation in the new technology platforms of Yingke Rui's characteristic new preparations such as aerosol inhalation solutions, nanogels, and in situ gels

Weikang Pharmaceutical: The decline in net profit in the fourth quarter was mainly due to the corresponding progress of some of the company's outsourced R&D projects in the fourth quarter

[Express] Weikang Pharma Announces Annual Report-CFi.CN

[Express] Weikang Pharma Announces Annual Report-CFi.CN

Are there any medications used to treat hepatitis? Weikang Pharmaceuticals responds

Weikang Pharmaceutical: The company's product, Gansu Capsules, reduces enzymes for chronic active hepatitis and hepatitis B

Weikang Pharmaceutical: The company's research product Huangjia Ruangan Granule is a 1.1 class of innovative traditional Chinese medicine drugs for chronic hepatitis B liver fibrosis

Weikang Pharmaceutical: The Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved traditional Chinese medicine.

Weikang Pharmaceutical: The company's product under development, Huangjia Ruangan Granules, is a class 1.1 innovative traditional Chinese medicine drug, which is used for chronic hepatitis B liver fibrosis.

Weikang Pharmaceutical: Net profit in 2021 is about 96.5 million yuan, a year-on-year decrease of 28.95%

Weikang Pharmaceutical: In 2022, the company will continue to deepen the pharmaceutical health industry and actively cultivate various businesses in line with the development strategy.

Weikang Pharmaceutical: In 2022, the company will continue to deepen the pharmaceutical and health industry and actively cultivate various businesses in line with the development strategy_ Oriental Fortune Net

Weikang Pharmaceutical: In 2022, the company will continue to deepen the development of the pharmaceutical and health industry, and actively cultivate various businesses in line with the development strategy.

Weikang Pharmaceutical: The company's product Yupingfeng Dripping Pills is a reference list of medical institutions in the Guangdong Provincial Health and Health Commission's reference list of supplies for the prevention and control of COVID-19.

Want to see more data? Registered subscribers can see all the data.